Knowledge Intensive Services
Chris Dunn shortlisted as a Top UK Business Adviser
Chris Dunn has been shortlisted for the UK’s Top Business Advisers Awards. Chris who delivers consulting, coaching, and mentoring services to help entrepreneurs grow their business was picked from hundreds of advisers from around the UK for his outstanding work in business development. ...
The EpiCentre is working with Microsoft to support innovative early-stage businesses
Oxford Innovation Space that manages The EpiCentre at Haverhill and Microsoft have announced that they are working together to support the growth of innovative early-stage businesses. ...
Chris Dunn Coaching goes live
Welcome to the Chris Dunn Coaching website - the home of impact and performance for leaders and aspiring leaders. ...
New Google to Microsoft 365 migration product by ShareGate
ShareGate has produced a new tool that should make it easier to undertake Google Workspace to Microsoft 365 migrations. ...
Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of PD-1 and PD-L1 molecules, they have resulted in cumulative 2023 global revenues exceeding $45 billion USD. Within the PD-...
The Epicentre launches a new growth accelerator programme to help its occupiers build for their future
The Epicentre at Haverhill has launched a growth accelerator programme to help its clients’ growth with two unique options to suit startups, R&D spinouts, and established SMEs ...
Strategies for combination therapy in oncology – Part three: Thinking outside the box
This article is published in PM360
The economic cost of living with a rare disease across Europe
Although rare diseases affect a relatively small number of patients, collectively there are an estimated 30 million people in Europe living with 6,000-7,000 known rare diseases (RDs). There is growing recognition of rare diseases as a public health concern, given the many social, mental...
Price achieved for first indication vs. ASMR
CRA Life Sciences continues its series on leveraging RADAR, its orphan drug data repository, with a focus on PMA trends between ASMR outcomes and average annual treatment costs. The analysis shows a clear correlation between the ASMR rating and the level of price achieved. Notably, ASMR...
Improving patient access to medicines targeting early-stage cancers in Europe
This article was published in ISPOR Value and Outcomes Spotlight